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Objective To develop a biologically safe £owcytometric susceptibility test that depends on detection and
enumeration of activelygrowingMycobacterium avium organisms in drug-free and antimycobacterial agent-
containingmedium.
Methods Prior to analysis by £owcytometry, allM.avium susceptibility test samples were inactivated by
exposure to paraformaldehyde.The susceptibilities of 20 clinical isolates ofM.avium to amikacin,
cipro£oxacin, clarithromycin, and rifabutinwere tested by the £owcytometric and BACTECmethods.
Results Agreement was 97% between the results of the twomethods.The results of £owcytometric
susceptibility tests were available 24 h after inoculation of drug-containingmedium, while the BACTEC
method required 4^8 days to complete.
Conclusions The £owcytometric assay is safe, simple and reproducible.
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I N T R O D U C T I O N
In the last two decades, the Mycobacterium avium complex
(MAC), including M. avium and M. intracellulare, has become
the most common mycobacterium recovered from patient
specimens in the developed world [1^3]. The increasing inci-
dence of MAC disease is largely due to the epidemic of
acquired immunode¢ciency syndrome (AIDS) [3^7]. MAC
has been associated with approximately 90% of patients with
AIDS [8]. Most patients with AIDS or symptomatic MAC
infection develop disseminated multi-organ disease accompa-
nied by continuous high-grade mycobacteremia [4^7,9^13]. In
addition, infection with MAC is a signi¢cant problem in
other groups of immunocompromised individuals, including
those with cancer, chronic obstructive pulmonary disease,
cystic ¢brosis and diabetes mellitus [1,3,7]. Recently, reports
have also suggested that MAC pulmonary disease can occur in
individuals without predisposing conditions [5,14].
Currently, a standardized method for susceptibility testing
of MAC does not exist [3,13,15^18]. The broth method has
been reported to be more reliable than the agar medium
[3,9,15,16]; however, most laboratories prefer to use the BAC-
TEC method, which requires 4^8 days of incubation before
results are available [3,9,15,16,18]. Unfortunately, susceptibility
testing for MAC continues to be problematic [1,2,5,9,18,19]. In
fact, susceptibility testing of initial MAC isolates has been
suggested to be inappropriate and unnecessary [3,9,17,20].
Despite these reservations, antimycobacterial susceptibility
testing of MAC continues to be performed. Because therapy
may be modi¢ed based on susceptibility results, it is not sur-
prising that considerable e¡orts have been made to develop
rapid and accurate tests for susceptibility testing of MAC
[1,2,18,21,22].
Recently, we showed that accurate susceptibility testing of
M. tuberculosis could be accomplished rapidly by enumeration
of mycobacterial cells with a £ow cytometer [19]. Results of
tests were available 72 h after M. tuberculosis organisms were
incubated with antimycobacterial agents. In this report, we
demonstrate that enumeration of mycobacterial cells by £ow
cytometry can be used to detect the susceptibility or resistance
of clinical isolates ofM.avium to amikacin, cipro£oxacin, clar-
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ithromycin and rifabutin 24 h after initiation of the testing
procedure.
M A T E R I A L S A N D M E T H O D S
Antimycobacterial agents
Amikacin, cipro£oxacin, clarithromycin and rifabutin were
obtained fromUS Pharmacopeia (Rockville, MD, USA). For
£ow cytometry, stock solutions of amikacin and cipro£oxacin
were prepared at 1000mg/Lwith distilled water and sterilized
by ¢ltration with a 0.2-mm ¢lter (Nalgene Labware Division,
Rochester, NY, USA). Clarithromycin and rifabutinwere also
prepared at 1000mg/L, but ¢rst dissolved in 0.4mL of metha-
nol (EM Science Industries, Inc., Gibbstown, NJ, USA). The
pH of the stock solution of clarithromycin was adjusted to 6.5
with 0.1M phosphate bu¡er. Clarithromycin and rifabutin
were then incubated at 37 C for 24 h for self-sterilization.
Additional stock solutions were prepared for the radiometric
broth method. These stock solutions were prepared similarly,
except that amikacin was prepared at 360mg/L and 80mg/L,
cipro£oxacin at 160mg/L and 40mg/L, clarithromycin at
1280mg/L and 80mg/L, and rifabutin at 80mg/L and 4.8
mg/L. Aliquots of 1.0mL of the sterilized antimycobacterial
agents were frozen and stored atÿ70 C until use.
Mycobacteria and preparation
Twenty clinical isolates of M. avium that varied in their resis-
tance to antimycobacterial agents were obtained from theWis-
consin State Laboratory of Hygiene (WSLH, Madison,WI,
USA). M. avium isolate 141 was obtained from the National
Jewish Medical and Research Center (Denver, CO, USA).
Initially, each isolate was grown in 7H9 broth (Difco, Detroit,
MI, USA) at 37 Cwith 7^8% CO2 for approximately 5 days
until the turbidity of the suspensions was equivalent to a
McFarland 0.5 standard (1.0 108 CFU/mL). Each suspension
was then dispensed in 1.0-mL aliquots into 1.5-mL screw-cap
tubes (Sarstedt, Newton, NC, USA) and stored at ÿ70 C.
When needed, a frozen suspension of each isolate ofM. avium
was thawed and an aliquot of 50 mLwas used to inoculate 20
mL of fresh 7H9 broth in sterile 50-mL polypropylene screw-
cap tubes (Sarstedt). Cultures were incubated for 72 h at 37 C
in the presence of 7^8%CO2..The cultures were then used for
susceptibility testing when the turbidity was equivalent to a
McFarland 0.5 standard. Only log-phase cultures ofM. avium
were used for susceptibility testing.
Flow cytometric susceptibility testing
Aliquots of 0.5mL of each actively growing M. avium isolate
were transferred to 1.5-mL polypropylene screw-cap micro-
tubes (Sarstedt). The tubes were then inoculated with 0.5mL
of: 64, 32, 16, 8, 4, 2, 1, 0.2, 0.02 or 0.002mg of amikacin/L; 32,
16, 8, 4, 2, 1, 0.5, 0.25, 0.1, 0.02 or 0.002mg of cipro£oxacin/L;
256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.1, 0.02 or 0.002mg of
clarithromycin/L; and 16, 8, 4, 2, 1, 0.5, 0.24, 0.1, 0.02 or 0.002
mg of rifabutin/L to produce ¢nal concentrations of half of
these amounts. Drug-free controls ofM. aviumwere also pre-
pared by inoculating themwith 0.5mL of 7H9 broth (Difco).
Thereafter, the suspensions were incubated for 24 h at 37 C in
an environment of 7^8% CO2. After incubation, 0.2mL of
each assay suspension was removed and placed in a sterile 1.5-
mL screw-capmicrotube containing 57 mL of 8% paraformal-
dehyde (pH 7.4) and 0.2mL of sterile phosphate-bu¡ered sal-
ine (¢nal paraformaldehyde concentration was 1%). Samples
were mixed and held at room temperature for 45min before
being analyzed with a Bryte HS £ow cytometer with Win-
Bryte software (Bio-Rad Laboratories, Hercules, CA, USA).
Samples ¢xedwith paraformaldehyde were periodically tested
for viable cells by plating 0.01mL of the suspension on 7H10
agar medium (Difco). Subsequently, the plates were incubated
at 37 C for 14 days. No viable M. avium cells were detected.
After treatment with paraformaldehyde, M. avium cells were
detected and di¡erentiated from non-M. avium particles in
7H9 medium by £ow cytometry using forward and side-
angle light scatter signals. Electronic noise and background
particles in the 7H9 medium were excluded from analysis by
adjusting the threshold monitor listed on theWinBryte soft-
ware program. Forward and side-angle light scatter were then
used to analyze M. avium cells that were incubated with or
without antimycobacterial agents. For each sample acquired,
the £ow cytometer provided a histogram pro¢le showing the
number of M. avium organisms in each of 2048 logarithmic
channels of increasing light scatter. Five thousand events were
acquired for each sample at a £ow rate of 2 mL/min. In addi-
tion, 2.5-mm polystyrene beads (Molecular Probes, Eugene,
OR,USA)were used daily for calibration of the instrument.
Flow cytometric susceptibility index
The susceptibility index was obtained bydividing the number
of M. avium cells (events) detected in the drug-containing
sample by the number ofM. avium cells in the drug-free con-
trol.The susceptibility index of the control is 1. An isolate was
considered susceptible if a susceptibility index of 0.65, 0.60,
0.55 or 0.55 or less was obtained after exposure to amikacin,
cipro£oxacin, clarithromycin and rifabutin, respectively. The
number ofM. avium organisms/mLwas obtained as part of the
£ow cytometric statistical analysis and was dependent upon
establishment of gates to eliminate electronic noise and back-
ground particles from themedium.
âåæVena et al Mycobacterium avium ¯ow cytometric susceptibility testing
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 366±373
Radiometric broth method (BACTEC)
Initially, 7H9 broths were inoculated (1mL) with each of the
isolates of M. avium (one isolate per broth). The cultures were
incubated for 24^48 h to obtain turbidity equivalent to a
McFarland 1.0 standard (3.0 108 CFU/mL). A separate BAC-
TEC12B vial (Becton Dickinson Diagnostic Instrument Sys-
tems, Sparks, MD, USA) was then inoculated (0.1mL) with
each of the isolates of M. avium. After incubation for 24 h at
37 C, aliquots (0.1mL) of those seed cultures (working sus-
pension) with a growth index (GI) of 999 detected with the
BACTEC 460 instrument were diluted 1: 10 and 1: 100 with
BACTEC diluting £uid. Subsequently, 0.1mL of the diluted
suspensions of M. avium was used to inoculate each of the
drug-containing BACTEC 12B vials and a drug-free control.
Frozen vials containing each antimycobacterial agent were
thawed, and 0.1mL was injected into BACTEC 12B vials
using a ¢xed-needle allergist syringe (Becton Dickinson).The
¢nal concentrations were: 2.0mg and 8.0mg of amikacin/L;
1.0mg and 4.0mg of cipro£oxacin/L; 2.0mg and 32.0mg of
clarithromycin/L; and 0.12mg and 2.0mg of rifabutin/L.The
vials were then incubated at 37 C and tested with the BAC-
TEC 460 instrument at approximately the same time each day.
The minimum inhibitory concentration (MIC) was interpre-
table when the GI of the 1: 100 control read 20 or more for
three consecutive days while the GI of the undiluted control
read 999. These requirements had to be met between days 4
and 8 of incubation for the test to be considered valid. The
MIC was the lowest concentration of the antimycobacterial
agent that inhibited 99% of the bacterial population.The ¢nal
GIwas less than 50.
Statistical analysis
A t-test was used to determine signi¢cant di¡erences between
the number of mycobacteria in the drug-free and drug-con-
tainingmedia.The alpha levelwas set at 0.05 before the experi-
ments were started.
R E S U L T S
Determination of optimal incubation time for detection of
M. avium after exposure to antimycobacterial agents by
¯ow cytometry
M. avium isolate 933 was incubated in the presence of 0.01,
0.5, 2.0 or 8.0mg/L of amikacin, cipro£oxacin, clarithromy-
cin and rifabutin or in the absence of these antimycobacterial
agents for 24 or 48 h before samples were analyzed by £ow
cytometry (Figure 1). The number of M. avium organisms
detected in each culture containing 2.0 or 8.0 mg of amikacin,
0.5, 2.0 or 8.0 mg of cipro£oxacin or clarithromycin and 0.01,
0.5, 2.0 or 8.0 mg of rifabutin was signi¢cantly less (P< 0.01)
than the number of organisms detected in the drug-free con-
trols after a 24-h incubation.With a 48-h incubation, signi¢-
cantly fewer (P< 0.01) M. avium organisms were detected in
all antimycobacterial-containing samples, except those con-
taining 0.01mg/L of amikacin, cipro£oxacin or clarithromy-
cin. Similar results were obtained when these studies were
repeated with nine additional isolates of M. avium. In subse-
quent studies we therefore routinely used a 24 -h incubation to
determine the susceptibilities or resistances of isolates of M.
avium to antimycobacterial agents. Only in the unusual cir-
cumstance of a slowly growing isolate were results reported
from samples incubated for 48 h.
Susceptibility of clinical isolates of M. avium to
antimycobacterial agents
Eleven clinical isolates of M. avium with susceptibilities to
amikacin, cipro£oxacin, clarithromycin and rifabutin pre-
viously established by the tuberculosis unit of theWSLHwere
tested for susceptibility to these four antimycobacterial agents
with the 24 -h £ow cytometric technique. Figure 2 shows the
£ow cytometric susceptibility index values obtained with
three isolates of M. avium each exposed to amikacin (isolates
175, 244 and 768), cipro£oxacin (isolates 141, 250 and 730),
clarithromycin (isolates 141, 510 and 825) or rifabutin (isolates
244, 266 and 455). Isolate 175 was susceptible to 0.5mg or
more of amikacin/L, whereas isolate 244 was susceptible to
8.0mg or more of amikacin/L (Figure 2a). Isolate 730 was
resistant to all concentrations of cipro£oxacin. Isolate 141was
susceptible to 0.5mg or more of clarithromycin/L (Figure 2b),
while isolate 510 was susceptible only to 32.0mg or more of
clarithromycin/mL. By contrast, isolate 768 was resistant to all
concentrations of amikacin tested. Isolates 141 and 250 were
susceptible to 0.25mg and 4.0mg or more of cipro£oxacin/L,
respectively (Figure 2c). Isolate 825 was resistant to all the con-
centrations of clarithromycin tested. Isolate 455 was resistant
to all concentrations of rifabutin, while isolates 266 and 244
were susceptible to 0.05mg and 2.0mgormore of rifabutin/L,
respectively (Figure 2d).
Comparison of susceptibility test results by the ¯ow
cytometric and BACTEC methods
Twenty isolates of M. avium were tested for susceptibility to
amikacin, cipro£oxacin, clarithromycin and rifabutin by the
£ow cytometric and BACTEC methods (Table1). Agreement
(95%) between the methods was reached for 37 of the 39 tests
performed on amikacin (2.0mg/L), cipro£oxacin (1.0mg/L),
clarithromycin (2.0mg/L) and rifabutin (0.12mg/L).The two
exceptions were isolates 933 and 045, which were resistant to
2.0mg of amikacin/L or 1.0mg of cipro£oxacin/L by £ow
cytometry, but susceptible to these concentrations of amikacin
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or cipro£oxacin by the BACTEC method.When higher con-
centrations of amikacin (8.0mg/L), cipro£oxacin (4.0mg/L),
clarithromycin (32.0mg/L) and rifabutin (2.0mg/L) were
tested by the £ow cytometric and BACTEC methods, how-
ever, agreement was 100%. The overall agreement was 97%
(76 of 78 tests).
Reproducibility
Table 2 shows the reproducibility of the £ow cytometric sus-
ceptibility test. Four isolates (266, 045, 141, 569) with varying
susceptibilities to amikacin, cipro£oxacin, clarithromycin or
rifabutin were tested four times. Isolates 266, 045, 141 and 569
had susceptibility indices of 0.62 þ 0.02, 0.63 þ 0.03, 0.50 þ
0.02 and 0.75 þ 0.06 for amikacin (2.0mg/L), cipro£oxacin
(1.0mg/L), clarithromycin (2.0mg/L) and rifabutin (0.12mg/
L), respectively. Similar reproducibility was achieved with the
higher concentrations of amikacin, cipro£oxacin, clarithro-
mycin and rifabutin.
D I S C U S S I O N
There is no standard method for performing susceptibility
testing of isolates of MAC [3,13,15^18]. Conventional meth-
ods used for susceptibility testing of M. tuberculosis [23] are
generally not recommended for testingMAC [1^3,11,13,15]. In
fact, susceptibility testing of MAC is not recommended by
the Centers for Disease Control and Prevention [18]. Despite
these concerns, many clinical mycobacteriology laboratories
continue to perform susceptibility testing for MAC, because
Figure 1 Number of M. avium cells (events)/mL detected by ¯ow cytometry with or without (&) exposure to 0.01 (~), 0.5 (W), 2.0
(^) or 8.0 (&) mg/L of amikacin (a), clarithromycin (b), cipro¯oxacin (c), or rifabutin (d) for 24 or 48 h. The experimental error was
0.26, 0.24, 0.15 and 0.11 for amikacin (a), clarithromycin (b), cipro¯oxacin (c), and rifabutin (d), respectively.
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clinicians, especially those with extensive experience with
mycobacterial disease, ¢nd susceptibility testing of MAC use-
ful for guiding therapy. The most commonly used methods
are the BACTEC TB [3,9,15,16,18] and quantitative minimal
inhibitory or bactericidal concentration methods [1,19,24].
However, considerable e¡orts have been made to develop fas-
ter, more accurate, more reliable and biologically safe suscept-
ibility testing methods for predicting clinical e¤cacy of
antimycobacterial agents [1,16,18,25].
Our results show that susceptibility testing of M. avium
can be accomplished rapidly by using a £ow cytometer; test
results are available within 24^48 h, compared to 4^8 days
with the BACTEC method [3,9,15,16,18]. The assay depends
on detection and enumeration of actively growing M. avium
organisms in drug-free and antimycobacterial agent-contain-
ing media. In addition, the assay was safe. Mycobacteria were
killed by exposure to paraformaldehyde before analysis with a
£owcytometer.
Our £ow cytometric test results of 20 clinical isolates of
M. avium for susceptibility to amikacin, cipro£oxacin, clari-
thromycin and rifabutin agreed with the BACTECmethod in
76 of the 78 (97%) tests performed. The only discrepancies
(two tests) were M. avium isolates 933 and 045, which were
resistant to 2.0mg of amikacin/L and 1.0mg of cipro£oxacin/
L by the £owcytometric method, but susceptible by the BAC-
TECmethod.When higher concentrations of these antimyco-
bacterial agents were tested, both isolates were susceptible to
amikacin or cipro£oxacin by the £ow cytometric and BAC-
Figure 2 Susceptibility index values of different isolates of M. avium (^ 768, & 244, W175 for (a); ^825, & 510, W 141
for (b); ^730, & 250, W 141 for (c); and ^ 455, & 244, W266 for (d), with or without exposure to selected concentra-
tions of amikacin (a), clarithromycin (b), cipro¯oxacin (c), or rifabutin (d) for 24 h.
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TEC methods. A likely explanation for the discrepancies lies
in the cut-o¡ value for the £ow cytometric susceptibility
index.We conservatively set the cut-o¡ value at 0.65 and 0.60
for amikacin and cipro£oxacin, respectively. When the sus-
ceptibility index value was raised to 0.67 or 0.61, these isolates
were categorized as susceptible to amikacin or cipro£oxacin.
Table 1 Results of susceptibility tests by the ¯ow cytometric and BACTEC methods for isolates of M. avium exposed to amikacin, cipro¯oxa-
cin, clarithromycin or rifabutin.
Results obtained by:
Flow cytometric method BACTEC method
Amikacin 2.0 mg/L 8.0 mg/L 2.0 mg/L 8.0 mg/L
028 S S S S
045 R S R S
141 R S R S
175 S S S S
244 R S R S
266 S S S S
316 R R R R
569 R S R S
768 R R R R
923 R R R R
933 R S S S
Cipro¯oxacin 1.0 mg/L 4.0 mg/L 1.0 mg/L 4.0 mg/L
045 R S S S
141 S S S S
244 S S S S
250 R S R S
569 R R R R
730 R R R R
768 R S R S
871 R R R R
933 S S S S
Clarithromycin 2.0 mg/L 32.0 mg/L 2.0 mg/L 32.0 mg/L
077 S S S S
141 S S S S
250 R R R R
510 R S R S
730 R S R S
768 R R R R
776 S S S S
825 R R R R
933 S S S S
Rifabutin 0.12 mg/L 2.0 mg/L 0.12 mg/L 2.0 mg/L
141 R S R S
175 S S S S
244 R S R S
266 S S S S
316 R S R S
354 R R R R
455 R R R R
569 R S R S
871 R R R R
933 S S S S
Isolates of M. avium were exposed to 2.0 or 8.0 mg of amikacin/L, 1.0 or 4.0 mg of cipro¯oxacin/L, 2.0 or 32.0 mg of clarithromycin/L and
0.12 or 2.0 mg of rifabutin/L using the ¯ow cytometric and BACTEC methods. Isolates marked `S' for ¯ow cytometry had susceptibility
indexes of 0.65, 0.60, 0.55 and 0.55 or less after exposure to amikacin, cipro¯oxacin, clarithromycin and rifabutin, respectively, for 24 h. The
isolates marked `S' for the BACTEC method showed less than 1% of growth detected in the drug-free control vials after 4±8 days of
incubation. Isolates marked `R' for both methods were considered to be resistant.
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This minor adjustment in the susceptibility index resulted in
complete agreement between the £ow cytometric susceptibil-
ity test and BACTEC method. Although testing of more iso-
lates might ¢ne-tune the best-¢t cut-o¡ values, these values
are unlikely to di¡er greatly from our selected values for ami-
kacin (0.65), cipro£oxacin (0.60), clarithromycin (0.55) and
rifabutin (0.55).
The £ow cytometric susceptibility test required only 24 h
after initiation of the testing procedure to obtain results. By
contrast, the BACTEC method required 4^8 days of incuba-
tion before the susceptibility results were available
[3,9,15,16,18]. Furthermore, approximately 15% of the results
obtained by BACTEC required replication of the procedure.
This further delayed reporting of results. Occasionally, slow-
growing isolates of M. avium also delayed results of the £ow
cytometric susceptibility test. However, results were available
after incubation for an additional 24 h after the initial £ow
cytometric analysis. Although we reported isolates 045 and
933 as resistant to 2.0mg of amikacin/L and 1.0mg of cipro-
£oxacin/L, respectively, these isolates were susceptible to these
concentrations of amikacin or cipro£oxacin after incubation
for 48 h.This is a major advantage of the £ow cytometric sus-
ceptibility test procedure. The original suspensions of M.
aviumwith or without antimycobacterial agents can be re-ana-
lyzed daily, if necessary. The BACTEC method, however,
would require inoculation of a new set of 12B medium with
and without antimycobacterial agents and incubation for 4^8
days before results become available.
Another major advantage of the £ow cytometric suscept-
ibility test is that it can generate a quantitative MIC. Multiple
concentrations of each antimycobacterial agent can be tested
with little additional expense or time. By contrast, the BAC-
TEC method uses two points or critical concentrations to
obtain results.The broad variation in the degree of susceptibil-
ity or resistance among isolates ofM. avium is a valid argument
against employing only critical concentrations for determina-
tion of results [15]. BACTEC can, of course, be performed
with multiple concentrations of antimycobacterial agents, but
this would increase the cost of the procedure. Finally, the large
size of the inoculum used in the £ow cytometric studies has a
distinct advantage. Drug-resistant mutants have been found
by daily re-analysis of the suspensions of M. avium with or
without antimycobacterial agents. The larger the inoculum,
the greater the chance of detecting resistant organisms.
Expanded studies are still needed, however, to correlate the
¢ndings obtained by £ow cytometry to the clinical outcome
ofM.avium disease in patients.
We showed previously that £ow cytometry could also be
used for susceptibility testing of M. tuberculosis [26^29] and
other mycobacteria [21]. A major concern about £ow cyto-
metric testing of pulmonary pathogens has always been bio-
safety. It is possible that aerosolization of mycobacteria could
occur during processing of the drug-free and drug-containing
samples. Recently, we showed that treatment of the £ow cyto-
metric susceptibility suspensions with 1% paraformaldehyde
eliminates the risk of infection to healthcare workers using the
£ow cytometer. No viable tubercle bacilli were recovered
from the drug-containing or drug-free suspensions 40min
after treatment with paraformaldehyde. Accurate results could
still be obtained, however, if the paraformaldehyde samples
were analyzed 24 or 72 h after treatment. In this study, all sam-
ples containing isolates ofM. aviumwere treated with parafor-
Table 2 Reproducibility of the ¯ow cytometric susceptibility test for four isolates of M. avium with varying susceptibilities and resistances to
amikacin, cipro¯oxacin, clarithromycin or rifabutin.










266 Control 1.00 0.00
S Amikacin (2.0 mg/L) 0.62 0.02
S Amikacin (8.0 mg/L) 0.54 0.03
045 Control 1.00 0.00
R Cipro¯oxacin (1.0 mg/L) 0.63 0.03
S Cipro¯oxacin (4.0 mg/L) 0.57 0.01
141 Control 1.00 0.00
S Clarithromycin (2.0 mg/L) 0.50 0.02
S Clarithromycin (32.0 mg/L) 0.42 0.04
569 Control 1.00 0.00
R Rifabutin (0.12 mg/L) 0.75 0.06
S Rifabutin (2.0 mg/L) 0.41 0.06
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maldehyde, and no viable mycobacteria were recovered on
7H10 agar medium after treatment with paraformaldehyde
and incubation for 3weeks. Treatment of samples with paraf-
ormaldehyde therefore e¡ectively eliminates concerns about
the biosafety of the procedure.
We conclude that the advantages of speed, simplicity, repro-
ducibility and safety o¡ered by £ow cytometry make it the
method of choice for susceptibility testing ofM. avium recov-
ered from clinical infections.
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